MedDataX Logo

Burst Biologics Spinal Fusion Registry

NCT ID: NCT03064802

Last Updated: 2019-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-24

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter patient registry was created with aim of documenting how spine and neurosurgeons are utilizing Burst Biologics products along with patient outcomes. These include radiographic measures such as fusion outcome, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on surgeon and patient based outcome assessments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spinal fusion surgery remains the most common intervention despite the increasing prevalence of various motion preservation and alternative stabilization devices for patients who are unresponsive to conservative treatment and experience back and/or leg pain and decreased function/quality of life. Donor site morbidity and availability limit the use of autogenous bone and over the past two decades' surgeon interest in alternative bone grafts has steadily increased. Bone morphogenic proteins, synthetic bone graft substitutes, and various allograft products are widely available to surgeons. Limitations on the use of allografts in the past were mainly attributed to less than optimal donor screening and processing techniques which removed viable components needed to aid in the bone healing process.

In recent years, the focus and scientific advances in various allograft processing techniques have allowed the retention of various viable cytokines, growth factors, and cell populations which result in enhanced osteogenic and osteoinductive properties. Rigorous donor bone screening and meticulous testing has virtually eliminated the risk of disease transmission.

A unique proprietary cryoprotection processing technique for allograft tissue was developed by Smart-Surgical, Inc. and a complete line of allograft products was created and is now marketed by Burst Biologics (dba). In addition, rigorous standardized laboratory assay techniques and statistical analysis provide consistency and uniformity of the biologically active components of Burst allograft products.

This prospective registry was designed as an observational study to ascertain how commercially available Burst Products are being used by surgeons performing spinal fusion as well as determining relevant patient outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease Spinal Stenosis Spondylitis Spondylolisthesis Herniated Disk

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

BioBurst Spinal Fusion Cellular Allograft

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BioBurst Fluid, Burst Allograft

Spinal Fusion with BioBurst Fluid or Burst Allograft

BioBurst Fluid, Burst Allograft

Intervention Type DEVICE

BioBurst Fluid or Burst Allograft used to augment spinal fusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BioBurst Fluid, Burst Allograft

BioBurst Fluid or Burst Allograft used to augment spinal fusion

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 18 years or older
* Patient diagnosed with a degenerative spine disorder, has failed conservative treatment, and has decided to undergo surgery.
* The surgeon has determined that a Burst Biologic product is or was clinically indicated.
* Patient capable of understanding the content of the Informed Consent Form
* Patient willing and able to participate in the registry protocol including follow-up visits and clinical evaluations.
* Patient who has agreed to participate in the registry by providing consent according to the applicable local law and the declaration of Helsinki.

Exclusion Criteria

The following are relative contraindications for the use of Burst Products, however the investigator surgeon is solely responsible for the determination of patient eligibility for surgery:

* Severe vascular or neurological disease
* Uncontrolled diabetes
* Severe degenerative disease (other than degenerative disc disease)
* Hypercalcemia, abnormal calcium metabolism
* Existing acute or chronic infections, especially at the site of the operation
* Inflammatory bone disease such as osteomyelitis
* Malignant tumors
* Patients who are or plan to become pregnant.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Burst Biologics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Burst Biologics

Medical Affairs Officer

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven M Czop, R.Ph.

Role: STUDY_DIRECTOR

Medical Affairs Officer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Carrollton Orthopaedic Clinic

Carrollton, Georgia, United States

Site Status RECRUITING

Orthopaedic Institute of Western Kentucky

Paducah, Kentucky, United States

Site Status RECRUITING

OrthoBethesda

Bethesda, Maryland, United States

Site Status RECRUITING

Cary Orthopedics

Cary, North Carolina, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Steven M Czop, R.Ph.

Role: CONTACT

Phone: 888-322-1191

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Brad G Prybis, MD

Role: primary

K. Brandon Strenge, MD

Role: primary

Joseph O'Brien, MD

Role: primary

Sameer Mathur, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SP001

Identifier Type: -

Identifier Source: org_study_id